Gene · 8405
Papers2,215
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
201 to 220 of 2,215
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Effect of ubiquitin protease system on DNA damage response in prostate cancer (Review). | Exp Ther Med | 2024 | 38125344 | PubTator, text mining | PubMed |
| Multi-omics approach for identifying CNV-associated lncRNA signatures with prognostic value in prostate cancer. | Noncoding RNA Res | 2024 | 38075203 | PubTator, text mining | PubMed |
| MZF1 promotes tumour progression and resistance to anti-PD-L1 antibody treatment in hepatocellular carcinoma. | JHEP Rep | 2024 | 38074509 | PubTator, text mining | PubMed |
| Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer. | Eur Urol Oncol | 2024 | 38072760 | PubTator, text mining | PubMed |
| UBE2J1 is the E2 ubiquitin-conjugating enzyme regulating androgen receptor degradation and antiandrogen resistance. | Oncogene | 2024 | 38030789 | PubTator, text mining | PubMed |
| Immunohistochemical markers as predictors of prognosis in multifocal prostate cancer. | Virchows Arch | 2024 | 38017230 | PubTator, text mining | PubMed |
| LRP5 competes for SPOP binding to enhance tumorigenesis mediated by Daxx and PD-L1 in prostate cancer. | Exp Cell Res | 2024 | 38008278 | PubTator, text mining | PubMed |
| SPOP promotes CREB5 ubiquitination to inhibit MET signaling in liver cancer. | Biochim Biophys Acta Mol Cell Res | 2024 | 37996058 | PubTator, text mining | PubMed |
| The Mutational and Transcriptional Landscapes of Speckle-Type POZ Protein (SPOP) and Androgen Receptor (AR) in a Single-Center pT3 Prostatectomy Cohort. | J Environ Pathol Toxicol Oncol | 2024 | 37824367 | PubTator, text mining | PubMed |
| Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial. | J Natl Cancer Inst | 2024 | 37676819 | PubTator, text mining | PubMed |
| Genetic Profiling of African American Patients With Prostatic Adenocarcinoma Metastatic to the Lymph Nodes: A Pilot Study. | Arch Pathol Lab Med | 2024 | 37327205 | PubTator, text mining | PubMed |
| Simple models to understand complex disease: 10 years of progress from Caenorhabditis elegans models of amyotrophic lateral sclerosis and frontotemporal lobar degeneration. | Front Neurosci | 2023 | 38239833 | PubTator, text mining | PubMed |
| Towards Understanding Neurodegenerative Diseases: Insights from Caenorhabditis elegans. | Int J Mol Sci | 2023 | 38203614 | PubTator, text mining | PubMed |
| miR-410 Is a Key Regulator of Epithelial-to-Mesenchymal Transition with Biphasic Role in Prostate Cancer. | Cancers (Basel) | 2023 | 38201476 | PubTator, text mining | PubMed |
| Cell-Free DNA Genomic Profiling and Its Clinical Implementation in Advanced Prostate Cancer. | Cancers (Basel) | 2023 | 38201475 | PubTator, text mining | PubMed |
| Retracted: HS3ST1 Promotes Non-Small-Cell Lung Cancer Progression by Targeting the SPOP/FADD/NF-κB Pathway. | Biomed Res Int | 2023 | 38188779 | PubTator, text mining | PubMed |
| Ubiquitin signaling in pancreatic ductal adenocarcinoma. | Front Mol Biosci | 2023 | 38174069 | PubTator, text mining | PubMed |
| Lipid kinases PIP5Ks and PIP4Ks: potential drug targets for breast cancer. | Front Oncol | 2023 | 38156113 | PubTator, text mining | PubMed |
| Addressing the Binding Mechanism of the Meprin and TRAF-C Homology Domain of the Speckle-Type POZ Protein Using Protein Engineering. | Int J Mol Sci | 2023 | 38139193 | PubTator, text mining | PubMed |
| Inflammation in Prostate Cancer: Exploring the Promising Role of Phenolic Compounds as an Innovative Therapeutic Approach. | Biomedicines | 2023 | 38137361 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8405/papers?page=11